The goal of this clinical study is to evaluate the safety and efficacy of autologous COVID-19 antigen specific T cell (LB-DTK-COV19) treatment in prolonged SARS-CoV-2 infected patients. The main questions it aims to answer are: * What adverse events occur after the infusion of LB-DTK-COV19? * Is there a clinically significant improvement in clinical symptoms within 4 weeks after the infusion? * Is there a clinically significant reduction in SARS-CoV-2 viral load within 4 weeks after the infusion? The patients will: * Receive a single infusion of LB-DTK-COV19 either intravenously or using central venous catheter during the baseline visit at a dose of 1x10\^7/m\^2. * Receive a second infusion of LB-DTK-COV19 either intravenously or using central venous catheter at the same dose 14 days after the first infusion. * Attend follow-up visits at the clinic for 6 months after the first infusion.
Age range
19 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Viral load
Timeframe: From the screening visit through 24 weeks after treatment initiation.
WHO Ordinal Scale
Timeframe: From the screening visit through 24 weeks after treatment initiation.
NEWS2 Score
Timeframe: From the screening visit through 24 weeks after treatment initiation.
Chest CT Severity Score
Timeframe: From the screening visit through 24 weeks after treatment initiation.
Quantification of SARS-CoV-2-Specific T cells
Timeframe: From the baseline visit through 24 weeks after treatment initiation.
SARS-CoV2-Specific T-cell Responses
Timeframe: From baseline through 24 weeks after treatment initiation.
Adverse Events
Timeframe: From the baseline visit through 24 weeks after treatment initiation.